Skip to Content

Aeglea BioTherapeutics Inc

Rating as of

Company Profile

Business Description

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.

805 Las Cimas Parkway, Suite 100
Austin, TX, 78746
T +1 512 942-2935
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Distressed
Employees 79